[
    [
        {
            "time": "2018-10-09",
            "original_text": "Novartis Announces Positive Sickle-cell Pain Trial",
            "features": {
                "keywords": [
                    "Novartis",
                    "Positive",
                    "Sickle-cell",
                    "Pain",
                    "Trial"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-10-09",
            "original_text": "Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study",
            "features": {
                "keywords": [
                    "Novartis",
                    "crizanlizumab",
                    "SEG101",
                    "patients",
                    "sickle cell",
                    "pain crises",
                    "placebo",
                    "SUSTAIN study"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-09",
            "original_text": "Considering Novartis’s Revenue Growth Rate",
            "features": {
                "keywords": [
                    "Novartis",
                    "Revenue",
                    "Growth",
                    "Rate"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 2,
                "Time_Proximity": 6,
                "Headline_Structure": 4,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-10-09",
            "original_text": "How Artificial Intelligence Is Helping Pharmaceuticals Develop Drugs",
            "features": {
                "keywords": [
                    "Artificial Intelligence",
                    "Pharmaceuticals",
                    "Develop",
                    "Drugs"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "technology",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-10-09",
            "original_text": "A Look at Novartis’s Valuation on October 9",
            "features": {
                "keywords": [
                    "Novartis",
                    "Valuation"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "finance"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 2,
                "Time_Proximity": 6,
                "Headline_Structure": 4,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-10-09",
            "original_text": "Assessing Novartis’s Performance in October So Far",
            "features": {
                "keywords": [
                    "Novartis",
                    "Performance",
                    "October"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "finance"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 2,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-10-09",
            "original_text": "In a small San Francisco office, Big Pharma zeroes in on digital health",
            "features": {
                "keywords": [
                    "Big Pharma",
                    "digital health",
                    "San Francisco"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "technology",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-10-09",
            "original_text": "Pre-Market Most Active for Oct 9, 2018: QQQ, PYX, NVS, GE, SQQQ, BABA, TVIX, SNAP, DB, ERIC, TLT, AFMD",
            "features": {
                "keywords": [
                    "Pre-Market",
                    "Most Active",
                    "Oct 9",
                    "QQQ",
                    "PYX",
                    "NVS",
                    "GE",
                    "SQQQ",
                    "BABA",
                    "TVIX",
                    "SNAP",
                    "DB",
                    "ERIC",
                    "TLT",
                    "AFMD"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "market",
                    "finance"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 3,
                "Sentiment": 4,
                "Importance": 3,
                "Impact": 2,
                "Duration": 2,
                "Entity_Density": 9,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 3,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-10-09",
            "original_text": "Ionis Pharmaceuticals: Recent Developments and Analysts’ Ratings",
            "features": {
                "keywords": [
                    "Ionis Pharmaceuticals",
                    "Recent Developments",
                    "Analysts’ Ratings"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals",
                    "finance"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 5,
                "Source_Recency": 4
            }
        }
    ]
]